Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference9 articles.
1. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer;Fukuoka;J Clin Oncol,2003
2. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer;Kris;J Am Med Assoc,2003
3. Selective oral epidermal growth factor receptor tyrosine kinse inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial;Herbst;J Clin Oncol,2002
4. Molecular evidence for the lack of epidermal growth factor receptor gene expression in small cell lung carcinoma cell;Gamou;Cancer Res,1987
5. In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor;Damstrup;Br J Cancer,1998
Cited by 37 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Unusual response with tyrosine kinase inhibitor in small-cell lung cancer;Annals of Oncology Research and Therapy;2024-07
2. Molecular and Genetic Advances in Small Cell Lung Cancer Landscape: From Homogeneity to Diversity;International Journal of Molecular Sciences;2023-12-22
3. Detection of clinically-relevant <em>EGFR</em> variations in <em>de novo</em> small cell lung carcinoma by droplet digital PCR;Monaldi Archives for Chest Disease;2022-09-02
4. Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report;Frontiers in Oncology;2021-03-18
5. Resistance to Both Chemotherapy and EGFR-TKI in Small Cell Lung Cancer With EGFR 19-Del Mutation: A Case Report;Frontiers in Oncology;2020-07-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3